CurveBeam AI Secures Device Orders, Advances China Partnership and FDA Filing in Q2 FY26

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialCurvebeam AI Ltd. ( (AU:CVB) ) just unveiled an update. CurveBeam AI reported receiving purchase orders for five imaging devices in its second quarter of fiscal 2026, including four HiRise systems and one LineUp unit, underscoring growing commercial uptake of its orthopedic imaging solutions. The company advanced its strategic collaboration with WEGO Orthopaedics’ subsidiary Shandong WeiYing in China, moving into implementation and technology transfer and triggering a A$4.0 million milestone equity investment, while WEGO began significant promotion of the US-manufactured HiRise under its existing Chinese regulatory registration. CurveBeam AI also submitted an FDA 510(k) application for a bone mineral density (BMD) module for MDCT scans, targeting clearance by mid-2026, and made progress toward validating HiRise’s compatibility with a leading robotic surgery system, steps that could broaden the clinical utility and addressable market of its technology and strengthen its competitive position in advanced orthopedic imaging and surgical planning. The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page. More about Curvebeam AI Ltd. CurveBeam AI Ltd. operates in the medical imaging technology sector, developing and commercialising advanced orthopedic and musculoskeletal imaging systems such as its HiRise and LineUp devices. The company focuses on integrating its imaging platforms into clinical workflows globally, including the Chinese market through partnerships, and is expanding its product offering with software modules designed for use with multi-detector CT (MDCT) scans and compatibility with robotic surgery systems. Average Trading Volume: 1,609,624 Technical Sentiment Signal: Sell Current Market Cap: A$37.9M For a thorough assessment of CVB stock, go to TipRanks’ Stock Analysis page.